That's it Koo. Pre-IND meeting soon for their lead xB3-001 candidate (xB3 with Herceptin) to treat patients with HER2+ breast cancer brain metastases. As of last update, this pre-IND meeting is to occur next month, with the IND submission and first in human trial for xB3-001 around mid-2020. The pre-IND meeting is to make sure that all their ducks are in a row and that everyone is on the same page for the path forward.

In addition to the MD&A that you found, here is the most recent corporate presentation:

https://bioasisprodcdn.azureedge.net/wp-content/uploads/BTI.V-Corporate-Presentation-April-2019-04.02.19.pdf

BearDownAZ